Edmond DE Rothschild Holding S.A. Boosts Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Edmond DE Rothschild Holding S.A. raised its position in Exact Sciences Co. (NASDAQ:EXAS) by 12.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 267,648 shares of the medical research company’s stock after purchasing an additional 29,026 shares during the period. Edmond DE Rothschild Holding S.A. owned 0.14% of Exact Sciences worth $15,039,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in EXAS. Asset Planning Inc purchased a new position in Exact Sciences during the fourth quarter worth about $40,000. Modus Advisors LLC purchased a new position in shares of Exact Sciences during the fourth quarter worth about $43,000. AlphaQuest LLC grew its holdings in shares of Exact Sciences by 22,825.0% during the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock worth $52,000 after purchasing an additional 913 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Exact Sciences in the fourth quarter worth approximately $66,000. Finally, Kieckhefer Group LLC bought a new stake in Exact Sciences during the fourth quarter valued at approximately $188,000. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on EXAS shares. Guggenheim set a $60.00 price target on shares of Exact Sciences and gave the stock a “buy” rating in a report on Friday. Piper Sandler lowered their price target on Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Scotiabank upped their price objective on Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. Bank of America decreased their price objective on Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, February 20th. Finally, Benchmark reaffirmed a “buy” rating and issued a $65.00 target price on shares of Exact Sciences in a research note on Monday, January 13th. Two analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $70.26.

Exact Sciences Stock Down 3.0 %

Shares of NASDAQ EXAS opened at $43.66 on Monday. The firm has a fifty day simple moving average of $49.71 and a two-hundred day simple moving average of $57.75. The firm has a market capitalization of $8.11 billion, a PE ratio of -7.84 and a beta of 1.25. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. Equities analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.